Community Health Media
  • Home
  • What We Do
  • Playlists
  • Content Library
    • HER2+
    • HR+
    • HER2-Low / Ultra-Low
    • Triple Negative
    • High Risk
  • Podcasts
    • Breast Friends
    • Apple Podcasts
    • Spotify
    • Amazon Music
    • iHeartRadio
    • Castbox
    • Goodpods
    • Pocket Casts
  • Contact Us
  • ···
        • Youtube
        • Facebook
        • LinkedIn
        • Instagram
    Community Health Media
    • Home
    • What We Do
    • Playlists
    • Content Library
      • HER2+
      • HR+
      • HER2-Low / Ultra-Low
      • Triple Negative
      • High Risk
    • Podcasts
      • Breast Friends
      • Apple Podcasts
      • Spotify
      • Amazon Music
      • iHeartRadio
      • Castbox
      • Goodpods
      • Pocket Casts
    • Contact Us
    • ···
          • Youtube
          • Facebook
          • LinkedIn
          • Instagram
      Community Health Media
      • Home
      • What We Do
      • Playlists
      • Content Library
        • HER2+
        • HR+
        • HER2-Low / Ultra-Low
        • Triple Negative
        • High Risk
      • Podcasts
        • Breast Friends
        • Apple Podcasts
        • Spotify
        • Amazon Music
        • iHeartRadio
        • Castbox
        • Goodpods
        • Pocket Casts
      • Contact Us

      The 12-Month Rule: Why Completing Neratinib Matters

      Completing all 12 cycles of Neratinib is essential for maximizing overall survival outcomes. Dr. Kang explains the dramatic difference in patient outcomes associated with treatment completion versus early discontinuation, and shares proactive management strategies to ensure patients receive the full benefit of therapy.

      FacebookXRedditPinterestEmail

      You may also like

      Video

      Dr. Jason Mouabbi, Dr. Irene Kang, and Dr. Ruemu Birhiray – Beyond pCR and Toward Brain Protection

      1 min read
      Video

      pCR Isn’t the Whole Story: How Oncologists Communicate Risk

      1 min read
      Video

      Why HER2+ Disease Has a Predisposition for Brain Metastases

      1 min read
      Video

      Should We Screen for Brain Metastases in HER2+ Disease?

      1 min read
      Video

      Does pCR Protect Against Brain Recurrence?

      1 min read
      Video

      Neratinib: Unique Reduction of CNS Recurrence Risk in the Extended Adjuvant Setting

      1 min read

      Recommended Videos

      DESTINY-Breast11, DESTINY-Breast05 & What Comes Next – Dr. Neil Iyengar & Dr. Komal Jhaveri

      4 months ago

      DESTINY-Breast09 & the Future of Care – Dr. Irene Kang & Dr. Aditya Bardia

      4 months ago

      Rethinking First-Line Metastatic HER2+ Therapy with T-DXd – Drs. Mouabbi, O’Shaughnessy & Rimawi

      4 months ago

      New First-Line Strategies in HER2+ Metastatic Breast Cancer – Dr. Mark Pegram & Dr. Carol Tweed

      4 months ago

      Community Health Ventures

      Address:

      2471 18th St NW
      Second Floor
      Washington, DC 20009

      Email: info@communityhealth.media

      Follow Us

      • youtube
      • facebook
      • linkedin
      • instagram

      Quick Links

      • About
      • KOL Playlists
      • Contact Us
      • Privacy Policy
      • Terms of Use

      Content By Topics

      • HER2+
      • HR+
      • Triple Negative
      • HER2-Low / Ultra-Low
      • High Risk

      Podcast Network

      • Breast Friends Podcast
      • Apple Podcasts
      • Spotify
      • Amazon Music
      • Castbox
      • Goodpods
      • iHeartRadio
      • Pocket Casts
      © 2026 Community Health Technologies, Inc. All Rights Reserved